Japan’s Eisai Co. obtained China rights to market and distribute two Parkinson’s disease treatments from Orion Corporation of Finland. The two products are Comtan® (entacapone) and Stalevo® (a levodopa/entacapone/carbidopa combination agent). PD is thought to be caused by dopamine deficiency, and Levodopa transforms into dopamine in the brain. Eisai, which operates in China through Eisai China, located in Suzhou, already markets a number of neurology products in China.
